James Hurst, vice president of Operations at Almac Pharma Services and site head of the organisation’s Charnwood facility in Loughborough, England, discusses the reasons to outsource formulation and development needs to CDMOs.
Key insights:
- Traditionally smaller pharma companies outsourced these activities, but there has been an increasing number of large-scale pharma companies utilising CDMOs for early phase development.
- Partnering with a CDMO for formulation development and manufacturing needs can provide a solution to help compress timelines and mitigate risk.
- Collaboration through a products development and commercial lifecycle can provide the client with access to teams with specialist knowledge and experience.
Partnering with a Contract Development and Manufacturing Organisation for your formulation development and manufacturing needs can provide a solution to help compress timelines and mitigate risk. A CDMO can provide services from early-stage clinical development through to clinical and commercial manufacturing and packaging, including full technical and analytical support, launch capabilities and final distribution. It is a compelling argument as to why engaging in this service model in the early stages of drug development can yield a positive process for all involved.